ACTRN12618000215224已完成未知
A low risk, open label, interventional Proof of Concept study to compare data collected simultaneously from S-patch and Holter ambulatory ECG devices.
Counties Manukau Health0 个研究点目标入组 90 人开始时间: 2018年2月9日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
终止
1 期
A Phase I clinical study to evaluate safety, tolerability and biological activity of platelet-derived extracellular vesicles on wound healing in healthy adultsWound healingSkin - Normal skin development and functionACTRN12619001378112Exopharm Ltd3
进行中（未招募）
1 期
Open label, First in human study for CX-2009 in adults with metastatic or locally advanced unresectable solid tumorsEUCTR2017-000625-12-DECytomX Therapeutics, Inc195
进行中（未招募）
1 期
Open label, First in human study for CX-2009 in adults with metastatic or locally advanced unresectable solid tumorsEUCTR2017-000625-12-NLCytomX Therapeutics, Inc563
进行中（未招募）
1 期
Open label, First in human study for CX-2009 in adults with metastatic or locally advanced unresectable solid tumorsMetastatic or locally advanced unresectable solid tumors in following indications: breast carcinoma, castration-resistant prostate carcinoma, non-small cell lung carcinoma, epithelial ovarian carcinoma, endometrial carcinoma, head and neck squamous cell carcinoma, or cholangiocarcinomaMedDRA version: 20.0Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000020935EUCTR2017-000625-12-ESCytomX Therapeutics, Inc150
进行中（未招募）
不适用
A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to evaluate the anti-tumor activity of the combination therapyocally advanced, non-resectable pancreatic adenocarcinomaMedDRA version: 8.1Level: LLTClassification code 10033604Term: Pancreatic cancerEUCTR2006-005314-12-DEWilex AG90